Among the single cell living organisms are bacteria, fungi, and plankton. Among the bacteria are very small structures initially discovered as fossils on a meteorite retrieved from Antarctica. While controversy exists as to their ability to actually live and reproduce in the manner of all biological organisms, these so-called nanobacteria are associated with specific diseases.
Among the diseases that may involve nanobacteria are kidney stones, which are precipirations of crystal in the urinary system. In many cases, these stones are composed at least partly of apatite crystal, which is also found in prostate stones (corpora amylacea). The incidence of prostate stones increases with age and with inflammation. Accordingly, it has proposed that nanobacteria are causally involved in the development of prostate inflammation and in clinical prostatitis. This proposal gains from two lines of investigation:
Using a rat model, investigators introduced nanobacteria through the urethra. In comparison with control animals, the rats exposed to nanobacteria developed acute inflammation within two weeks and then chronic inflammation soon after. By 8 weeks, most of the nanobacteria exposed rats had prostate stone formation. The tissue tested positive for nanobacteria in the rats so exposed but not in the control rats.
Patients with treatment-resistant chronic prostatitis were given a combination intervention of tetracycline antibiotic, a natural supplement of undisclosed ingredients, and a suppository of EDTA. Their symptom index score was measured with the CPSI and it dropped from 25 to 14. Imaging studies using ultrasound showed that prostate stone size decreased in half. Nanobacterial antigens were found in the blood of 60% of the patients. This study did not use a control group. The long-term safety of this protocol is not characterized.
Medical science generally knows little about nanobacteria. There is a theoretical basis for suggesting that they play a role in causing some cases of prostatitis. To understand this role well and to properly target anti-nanobacterial treatment will require more knowledge than we currently have.